PRLD Prelude Therapeutics Incorporated - Common Stock
$4,33
Preço · Mai 20, 2026
Fundamentais a partir de Mai 12, 2026
Intervalo 52 Semanas
$1–$6
75% of range
Classificação do Analista
BUY
9 analysts
Preço-Alvo
$7
+59% upside
P/E (TTM)
-2.2
ROE
-137.7%
Margem de Lucro Líquido
-819.6%
PRLD Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$4.33
Capitalização de Mercado
—
P/E (TTM)
-2.2
EPS (TTM)
$-1.29
Receita (TTM)
$12M
Rendimento div.
—
ROE
-137.7%
Dívida/Capital
—
Intervalo 52 Semanas
$1 – $6
PRLD Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$12M
2024-12-31
→
2025-12-31
EPS
$-1.29
2021-12-31
→
2025-12-31
Fluxo de caixa livre
$-56M
2020-12-31
→
2025-12-31
Margens
-819.6%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
PRLD
Mediana de Pares
P/E (TTM)
-2.2
9.4
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
PRLD
Mediana de Pares
Operating Margin (Margem Operacional)
-861.3%
—
Net Profit Margin (Margem de Lucro Líquido)
-819.6%
-205.9%
ROA
-62.8%
-30.4%
ROE
-137.7%
-54.4%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
PRLD
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
2.0
3.8
Quick Ratio (Índice de Liquidez Seca)
1.9
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
PRLD
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
73.4%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
PRLD
Mediana de Pares
PRLD Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
9 analistas
- Compra forte 3 33,3%
- Compra 5 55,6%
- Manter 1 11,1%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
4 analistas · 2026-05-14
Mediana
$7.00
← Abaixo de todos os alvos
$4.33
Mín
$4.50
Máx
$9.00
Alvo mediano
$7.00
+61,7%
Alvo médio
$6.88
+58,8%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.03%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 31 de Março de 2026 | $-0.13 | $-0.25 | 0.12% |
| 31 de Dezembro de 2025 | $-0.20 | $-0.03 | -0.17% |
| 30 de Setembro de 2025 | $-0.26 | $-0.37 | 0.11% |
| 30 de Junho de 2025 | $-0.41 | $-0.45 | 0.04% |
| 31 de Março de 2025 | $-0.42 | $-0.48 | 0.06% |
Comparação com pares Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| PRLD | — | -2.2 | 73.4% | -819.6% | -137.7% | — |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | — |
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| SABS | — | — | — | — | — | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 13
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Revenue | $12M | $7M | |
| R&D Expense | $94M | $118M | |
| SG&A Expense | $22M | $29M | |
| Operating Expenses | $117M | $147M | |
| Operating Income | $-105M | $-140M | |
| Other Non-op | $5M | $13M | |
| Income Tax | $0 | $0 | |
| Net Income | $-99M | $-127M | |
| EPS (Basic) | $-1.29 | $-1.68 | |
| EPS (Diluted) | $-1.29 | $-1.68 | |
| Shares (Basic) | 76,956,194 | 75,805,840 | |
| Shares (Diluted) | 76,956,194 | 75,805,840 | |
| EBITDA | $-103M | $-138M |
Balanço Patrimonial 18
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $35M | $12M | |
| Short-term Investments | $68M | $121M | |
| Prepaid Expense | $2M | $2M | |
| Current Assets | $106M | $136M | |
| PP&E (Net) | $5M | $7M | |
| PP&E (Gross) | $12M | $12M | |
| Accum. Depreciation | $7M | $5M | |
| Total Assets | $141M | $176M | |
| Accounts Payable | $4M | $8M | |
| Accrued Liabilities | $13M | $15M | |
| Current Liabilities | $53M | $26M | |
| Capital Leases | $15M | $15M | |
| Other Non-current Liabilities | $3M | $3M | |
| Total Liabilities | $73M | $44M | |
| Retained Earnings | $-683M | $-584M | |
| AOCI | $8.0K | $35.0K | |
| Stockholders' Equity | $69M | $131M | |
| Liabilities + Equity | $141M | $176M |
Fluxo de Caixa 11
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| D&A | $2M | $2M | |
| Stock-based Comp | $12M | $21M | |
| Restructuring | $1M | · | |
| Other Non-cash | $30M | $1M | |
| Operating Cash Flow | $-56M | $-103M | |
| CapEx | $67.0K | $764.0K | |
| Investing Cash Flow | $53M | $90M | |
| Financing Cash Flow | $25M | $-120.0K | |
| Net Change in Cash | $22M | $-13M | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-56M | $-104M |
Lucratividade 5
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -861.3% | -1995.9% | |
| Net Margin | -819.6% | -1816.8% | |
| EBITDA Margin | -847.2% | -1970.6% | |
| ROA | -62.8% | -56.1% | |
| ROE | -137.7% | -88.3% |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.0 | 5.3 | |
| Quick Ratio | 1.9 | 5.2 |
Eficiência 1
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 |
Taxas de Crescimento 1
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 73.4% | · |
Avaliação (TTM) 4
| Métrica | Tendência | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $12M | $7M | |
| Net Income TTM | $-99M | $-127M | |
| P/E | -2.2 | -0.8 | |
| Earnings Yield | -44.5% | -131.8% |
Demonstração de Resultados 12
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $6M | $6M | · | $0 | $4M | $3M | |
| R&D Expense | $14M | $18M | $22M | $26M | $29M | $32M | $29M | |
| SG&A Expense | $5M | $5M | $5M | $6M | $6M | $6M | $8M | |
| Operating Expenses | $19M | $23M | $27M | $32M | $35M | $38M | $37M | |
| Operating Income | $-14M | $-17M | $-20M | $-32M | $-35M | $-34M | $-34M | |
| Other Non-op | $4M | $891.0K | $693.0K | $963.0K | $3M | $5M | $2M | |
| Net Income | $-10M | $-16M | $-20M | $-31M | $-32M | $-29M | $-32M | |
| EPS (Basic) | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.37 | $-0.43 | |
| EPS (Diluted) | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.37 | $-0.43 | |
| Shares (Basic) | 82,519,981 | -151,156,365 | 76,132,337 | 75,993,941 | 75,986,281 | -151,548,215 | 75,855,949 | |
| Shares (Diluted) | 82,519,981 | -151,156,365 | 76,132,337 | 75,993,941 | 75,986,281 | -151,548,215 | 75,855,949 | |
| EBITDA | $-14M | · | $-20M | $-32M | $-34M | · | $-34M |
Balanço Patrimonial 18
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22M | $35M | $48M | $26M | $40M | $12M | $11M | |
| Short-term Investments | $60M | $68M | $7M | $47M | $59M | $121M | $142M | |
| Prepaid Expense | $3M | $2M | $3M | $4M | $3M | $2M | $3M | |
| Current Assets | $85M | $106M | $58M | $77M | $102M | $136M | $156M | |
| PP&E (Net) | $5M | $5M | $6M | $6M | $6M | $7M | $7M | |
| PP&E (Gross) | · | $12M | · | · | · | $12M | · | |
| Accum. Depreciation | · | $7M | · | · | · | $5M | · | |
| Total Assets | $120M | $141M | $95M | $115M | $141M | $176M | $197M | |
| Accounts Payable | $2M | $4M | $3M | $5M | $6M | $8M | $6M | |
| Accrued Liabilities | $6M | $13M | $13M | $13M | $11M | $15M | $14M | |
| Current Liabilities | $42M | $53M | $18M | $21M | $20M | $26M | $22M | |
| Capital Leases | $15M | $15M | $15M | $15M | $15M | $15M | $15M | |
| Other Non-current Liabilities | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Total Liabilities | $59M | $73M | $36M | $39M | $38M | $44M | $41M | |
| Retained Earnings | $-693M | $-683M | $-667M | $-647M | $-616M | $-584M | $-555M | |
| AOCI | $-41.0K | $8.0K | $2.0K | $-1.0K | $12.0K | $35.0K | $167.0K | |
| Stockholders' Equity | $60M | $69M | $59M | $76M | $103M | $131M | $156M | |
| Liabilities + Equity | $120M | $141M | $95M | $115M | $141M | $176M | $197M |
Fluxo de Caixa 10
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| D&A | $391.0K | $418.0K | $425.0K | $433.0K | $435.0K | $489.0K | $405.0K | |
| Stock-based Comp | $2M | $2M | $2M | $4M | $4M | $4M | $6M | |
| Restructuring | $0 | $851.0K | $0 | · | · | · | · | |
| Other Non-cash | $-14M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $-22M | $23M | $-19M | $-26M | $-34M | $-21M | $-27M | |
| CapEx | $0 | $0 | $0 | $20.0K | $47.0K | $53.0K | $63.0K | |
| Investing Cash Flow | $8M | $-60M | $40M | $12M | $62M | $22M | $11M | |
| Financing Cash Flow | $-314.0K | $25M | $-5.0K | $37.0K | $-160.0K | $-34.0K | $-131.0K | |
| Net Change in Cash | $-14M | $-12M | $21M | $-15M | $28M | $1M | $-17M | |
| Free Cash Flow | $-22M | · | · | · | $-34M | · | · |
Lucratividade 5
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -309.5% | · | -314.1% | · | · | · | -1145.9% | |
| Net Margin | -226.8% | · | -303.5% | · | · | · | -1075.7% | |
| EBITDA Margin | -301.0% | · | -314.1% | · | · | · | -1145.9% | |
| ROA | -8.0% | · | -13.5% | -18.4% | -16.5% | · | -14.2% | |
| ROE | -12.7% | · | -18.4% | -24.2% | -20.4% | · | -16.4% |
Liquidez e Solvência 2
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | · | 3.2 | 3.7 | 5.2 | · | 7.0 | |
| Quick Ratio | 2.0 | · | 3.0 | 3.5 | 5.0 | · | 6.9 |
Eficiência 1
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | · | · | · | 0.0 |
Avaliação (TTM) 3
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-93M | · | $-115M | $-130M | $-131M | · | $-129M | |
| P/E | -2.8 | · | -0.9 | -0.5 | -0.4 | · | -1.2 | |
| Earnings Yield | -35.7% | · | -105.6% | -212.6% | -225.3% | · | -85.0% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $12M | $7M | — | — | — |
| Margem Operacional % | -861.3% | -1995.9% | — | — | — |
| Lucro líquido | $-99M | $-127M | $-122M | $-115M | $-112M |
| EPS Diluído | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 2.0 | 5.3 | 10.8 | 9.4 | 15.4 |
| Índice de Liquidez Seca | 1.9 | 5.2 | 10.7 | 9.3 | 15.2 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-56M | $-104M | $-111M | $-87M | $-86M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.